Oasmia announces topline results from head-to-head comparison study of Paclical and A

[News]

Oasmia Pharmaceutical AB, developer of a new generation of drugs within human and veterinary oncology, announced today the topline findings from a head-to-head comparison study of its lead human cancer product candidate Paclical and Celgene's Abraxane, which show similar pharmacokinetic (PK) profiles of the two products. The study was conducted in women with metastatic breast cancer.

More... (http://www.news-medical.net/news/20150804/Oasmia-announces-topline-results-from-head-to-head-comparison-study-of-Paclical-and-Abraxane.aspx)